PHARMA NORD ApS: Financial statements 2023
CVR: 67303016
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
PHARMA NORD ApS (CVR 67303016) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 447,388,000 and a net result of DKK 23,337,000 compared with DKK 35,289,000 the year before. That is an increase of 1.8% compared with the year before. The profit margin was 5.2%. Equity in the 2023 report amounted to DKK 160,565,000. The solvency ratio was 37.6%. The company had 416 employees in the financial year.
- Revenue
- DKK 447,388,000
- Gross Profit
- DKK 147,581,000
- Profit/Loss
- DKK 23,337,000
- Equity
- DKK 160,565,000
- Total Assets
- DKK 427,094,000
- Employees
- 416
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 447.4 mio. | 147.6 mio. | 23.3 mio. | 160.6 mio. | 416 |
| 2022 | 439.4 mio. | 187.5 mio. | 35.3 mio. | 183 mio. | 425 |
| 2021 | 470.2 mio. | 221 mio. | 58 mio. | 199.3 mio. | 420 |
| 2020 | 417.2 mio. | 197.9 mio. | 51.9 mio. | 170.4 mio. | 394 |
| 2019 | 333 mio. | 126.1 mio. | 41.5 mio. | 269.7 mio. | 375 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
PHARMA NORD ApS has published its annual report for 2022. Revenue came to DKK 439,437,000, and the net result was DKK 35,289,000.
About PHARMA NORD ApS
PHARMA NORD ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 1981. The company is registered under the industry Fremstilling af andre fødevarer i.a.n.. The company was previously named DANMARKS HELSEKOST DISTRIBUTION ApS. The management consists of Eli Wallin. The board consists of Michael Christiani Havemann (chair) and Eli Wallin. The company is owned by PHARMCO I ApS and PharmCo III ApS. The company has 298 employees (2026). In 2025, the company reported revenue of DKK 518,005,000 and a net result of DKK 26,711,000 compared with DKK 32,254,000 the year before. Equity in the 2025 report amounted to DKK 181,417,000.